JAK2 and acute lymphoblastic leukemia: Targetable ABL-fusions (14.1%; ABL1(ABL), ABL2, CSF1R and PDGFRB), and EPOR rearrangements or JAK2 fusions (8.8%) have been identified in Ph-like ALL patients by RNA-sequencing [15,107].